| Companies sponsors |
Roche (mosunetuzumab) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
Blood Cancer UK |
| |
Leukaemia Care |
| |
Lymphoma Action |
| Professional groups |
Association of Cancer Physicians |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| Associated public health groups |
None |
| Comparator companies |
Bristol Myers Squibb (lenalidomide) (confidentiality agreement signed, participating) |
| |
Accord Healthcare (bendamustine) (confidentiality agreement not signed, not participating) |
| |
Dr Reddy’s Laboratories (bendamustine) (confidentiality agreement not signed, not participating) |
| |
Napp Pharmaceuticals (rituximab) (confidentiality agreement not signed, not participating) |
| |
Pfizer (rituximab) (confidentiality agreement not signed, not participating) |
| |
Roche (obinutuzumab, rituximab) (confidentiality agreement not signed, not participating) |
| |
Sandoz (rituximab) (confidentiality agreement not signed, not participating) |
| |
Seacross Pharmaceuticals (bendamustine) (confidentiality agreement not signed, not participating) |
| |
Zentiva (bendamustine) (confidentiality agreement not signed, not participating) |
| General commentators |
All Wales Therapeutics & Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |